The Warm Autoimmune Hemolytic Anemia Therapeutics Market Size in the 7MM was valued at ~USD 600 million in 2025 and It is expected to grow at a CAGR of 14.4% by 2036

The Warm Autoimmune Hemolytic Anemia Therapeutics Market Size in the 7MM was valued at ~USD 600 million in 2025 and It is expected to grow at a CAGR of 14.4% by 2036 | DelveInsight https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr https://www.abnewswire.com/email_contact_us.php?pr=the-warm-autoimmune-hemolytic-anemia-therapeutics-market-size-in-the-7mm-was-valued-at-usd-600-million-in-2025-and-it-is-expected-to-grow-at-a-cagr-of-144-by-2036-delveinsight https://www.delveinsight.com/report-store/warm-autoimmune-hemolytic-anemia-waiha-market (Albany, New York, USA), September 07, 2026- DelveInsight's "Warm Autoimmune Hemolytic Anemia Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of the Warm Autoimmune Hemolytic Anemia, historical and forecasted epidemiology and the Warm Autoimmune Hemolytic Anemia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.Download DelveInsight's comprehensive report to explore Warm Autoimmune Hemolytic Anemia market trends @Key Takeaways from the Warm Autoimmune Hemolytic Anemia Market Report* On August 31, 2026- Janssen Research & Development LLC initiated a study consists of a 24-week double-blind, placebo control period, a 144-week open-label extension period and follow-up period of 8 weeks after last study drug administration. Eligible participants will be randomized to placebo or nipocalimab (2 dose levels) during the double-blind period and nipocalimab (2 dose levels) during the open-label extension period.* On August 21, 2026- Sanofi conducted a phase 3 study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approximately 90 male and female participants greater than or equal to 18 years of age with a confirmed diagnosis of primary wAIHA.* In 2025, the total number of diagnosed prevalent cases of AIHA across the 7MM was estimated at approximately 120,000.* In the United States, primary wAIHA accounted for around 20,500 diagnosed prevalent cases in 2025, while secondary wAIHA comprised approximately 22,200 cases.* In 2025, females accounted for about 60% of diagnosed prevalent wAIHA cases across EU4 and the UK, while males represented around 40%.* In 2025, across EU4 and the UK, the greater than or equal to 65 age group accounted for around 55% of wAIHA cases, followed by the 45-64 age group at approximately 25%.* In 2025, in Japan, severe wAIHA accounted for around 420 cases, while non-severe cases were estimated at approximately 600.* The leading Warm Autoimmune Hemolytic Anemia Companies such as Johnson & Johnson, Sanofi, Novartis, Vertex Pharma, Incyte Corporation and others.* Promising Warm Autoimmune Hemolytic Anemia Therapies such as INCA000585, Povetacicept, Ianalumab, APL-2, Fostamatinib Disodium, ANX005, Fostamatinib 150 mg bid, Rilzabrutinib, HMPL-523(300mg PO QD) and others.Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Warm Autoimmune Hemolytic Anemia Treatment Market Size [Warm Autoimmune Hemolytic Anemia OverviewWarm Autoimmune Hemolytic Anemia (wAIHA) is a rare autoimmune blood disorder in which the immune system mistakenly produces antibodies, primarily immunoglobulin G (IgG), that bind to and destroy red blood cells at normal body temperature, typically around 37 degrees C. This premature destruction of red blood cells, known as hemolysis, can lead to anemia and symptoms such as fatigue, weakness, shortness of breath, jaundice, dizziness, and an increased heart rate. The condition may occur on its own (primary wAIHA) or be associated with underlying conditions such as autoimmune diseases, infections, certain cancers, or medications.Warm Autoimmune Hemolytic Anemia Epidemiology Segmentation in the 7MM* Total diagnosed prevalent cases of autoimmune hemolytic anemia* Total prevalent cases of wAIHA* Type-specific cases of wAIHA* Gender-specific cases of wAIHA* Age-specific cases of wAIHADownload the report to understand which factors are driving Warm Autoimmune Hemolytic Anemia epidemiology trends @ Warm Autoimmune Hemolytic Anemia Prevalence [Warm Autoimmune Hemolytic Anemia Market OutlookThe wAIHA market is entering a phase of transformation after decades of relying on broad immunosuppression with corticosteroids, rituximab, and other nonspecific immunosuppressants. These treatments often provide temporary disease control but are associated with frequent relapse, steroid dependence, and cumulative toxicity. Despite the significant disease burden, there are currently no therapies specifically approved for wAIHA in most major markets, highlighting a substantial unmet medical need.Warm Autoimmune Hemolytic Anemia Marketed Drugs* IMAAVY (nipocalimab): Johnson & JohnsonNipocalimab is an investigational monoclonal antibody that targets the neonatal Fc receptor (FcRn), inhibiting IgG recycling and reducing circulating pathogenic IgG antibodies. By lowering autoantibody levels, it has potential therapeutic benefits in IgG-mediated conditions such as warm autoimmune hemolytic anemia (wAIHA), where autoantibodies drive red blood cell destruction. Nipocalimab is currently being evaluated in a Phase II/III clinical trial for the treatment of warm wAIHA. In February 2026, Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) seeking approval of IMAAVY as a treatment for patients with wAIHA.Discover the future of Warm Autoimmune Hemolytic Anemia Treatments with DelveInsight's latest market report @ Warm Autoimmune Hemolytic Anemia Market Drivers and Barriers [Warm Autoimmune Hemolytic Anemia CompaniesJohnson & Johnson, Sanofi, Novartis, Vertex Pharma, Incyte Corporation and othersFrom market size to emerging drugs, find it all in our latest report. Read now! @ Warm Autoimmune Hemolytic Anemia Ongoing Clinical Trials Analysis [Scope of the Warm Autoimmune Hemolytic Anemia Market Report* Coverage- 7MM* Study Period- 2022-2036* Warm Autoimmune Hemolytic Anemia Companies- Johnson & Johnson, Sanofi, Novartis, Vertex Pharma, Incyte Corporation and others.* Warm Autoimmune Hemolytic Anemia Therapies- INCA000585, Povetacicept, Ianalumab, APL-2, Fostamatinib Disodium, ANX005, Fostamatinib 150 mg bid, Rilzabrutinib, HMPL-523(300mg PO QD) and others.* Warm Autoimmune Hemolytic Anemia Therapeutic Assessment: Warm Autoimmune Hemolytic Anemia Current marketed and Warm Autoimmune Hemolytic Anemia Emerging Therapies* Warm Autoimmune Hemolytic Anemia Market Dynamics: Warm Autoimmune Hemolytic Anemia market drivers and Warm Autoimmune Hemolytic Anemia market barriers* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies* Warm Autoimmune Hemolytic Anemia Unmet Needs, KOL's views, Analyst's views, Warm Autoimmune Hemolytic Anemia Market Access and ReimbursementTable of Contents* Key Insights* Report Introduction* Warm Autoimmune Hemolytic Anemia Market Overview at a Glance* Warm Autoimmune Hemolytic Anemia Epidemiology and Market Forecast Methodology* Warm Autoimmune Hemolytic Anemia Executive Summary* Key Events* Warm Autoimmune Hemolytic Anemia Disease Background and Overview* Warm Autoimmune Hemolytic Anemia Treatment and Management* Warm Autoimmune Hemolytic Anemia Epidemiology and Patient Population* Warm Autoimmune Hemolytic Anemia Patient Journey* Warm Autoimmune Hemolytic Anemia Marketed Therapies* Warm Autoimmune Hemolytic Anemia Emerging Therapies* Warm Autoimmune Hemolytic Anemia 7 Major Market Analysis* Warm Autoimmune Hemolytic Anemia KOL Views* Warm Autoimmune Hemolytic Anemia SWOT Analysis* Warm Autoimmune Hemolytic Anemia Unmet Needs* Warm Autoimmune Hemolytic Anemia Reimbursement Scenario* Warm Autoimmune Hemolytic Anemia Appendix* Warm Autoimmune Hemolytic Anemia DelveInsight Capabilities* DisclaimerAbout UsDelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail:Send Email [Phone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite:Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com